COMMUNITY CASE STUDY article
Front. Public Health
Sec. Substance Use Disorders and Behavioral Addictions
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1521911
Co-design of the Australian Prompt Response Network for a public-health focused intersectoral approach to information sharing on emerging drugs of concern
Provisionally accepted- 1the National Centre for Clinical Research on Emerging Drugs, Sydney, Australia
- 2Alcohol and Drug Service, St Vincent’s Hospital Sydney, Darlinghurst, New South Wales, Australia
- 3National Drug and Alcohol Research Centre, Faculty of Medicine, University of New South Wales, Randwick, New South Wales, Australia
- 4Drug and Alcohol Clinical Research and Improvement Network, Sydney, Australia
- 5New South Wales Ministry of Health, Artarmon, Australia
- 6New South Wales Poisons Information Centre, Sydney Children's Hospital Network, Westmead, New South Wales, Australia
- 7Forensic Science SA, Adelaide, Australia
- 8Harm Reduction Victoria, Melbourne, Victoria, Australia
- 9Peer Based Harm Reduction WA, Perth, Australia
- 10Population Health Division, ACT Health Directorate, Canberra, Australia
- 11Australian Injecting and Illicit Drug Users League (AIVL), Turner, Australian Capital Territory, Australia
- 12NSW Users and AIDS Association (NUAA), Sydney, Australia
- 13National Drug Research Institute and enAble Institue, Curtin University, Perth, Australia
- 14Department of Health, Victoria, Melbourne, Victoria, Australia
- 15Australian Drug Education and Consultancy, Bellevue, Australia
- 16School of Psychological Sciences, College of Health and Medicine, University of Tasmania, Hobart, Australia
- 17Northern Territory AIDS and Hepatitis Council (NTAHC), Darwin, Northern Territory, Australia
- 18Emergency Medicine, Royal Perth Hospital, Perth, Western Australia, Australia
- 19Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia
- 20Pill Testing Australia, Canberra, ACT, Australia
- 21Directions Health Services, Canberra, ACT, Australia
- 22Canberra Alliance for Harm Minimisation & Advocacy (CAHMA), Canberra, ACT, Australia
- 23St Vincent’s Hospital Sydney, Darlinghurst, New South Wales, Australia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The rapid emergence of new psychoactive substances (NPS) and other emerging drugs of concern presents a significant global public health challenge, necessitating agile and interconnected drug information systems to identify and communicate risks. In Australia, responses have traditionally been localised, lacking a nationally coordinated system to rapidly share information about emerging drug threats. The National Centre for Clinical Research on Emerging Drugs (NCCRED) collaborated with jurisdictional networks, clinicians, scientists, policy-makers and peer organisations to co-design and co-produce the national Prompt Response Network ("PRN"). This process identified key components necessary to create an effective healthfocused national network that supports and enhances existing and emerging jurisdictional and specialist early warning networks. The co-creation process resulted in several outputs, including a formalised national PRN group, an online knowledge exchange platform, a national website for disseminating drug alerts, and identified needs for a national drug signal database and an anecdotal reporting system.The PRN is the first Australian national public-health-focused mechanism for information exchange on new and emerging drugs and drug trends of concern. It provides the means for timely and responsive sharing of localised data, better informing risk assessment and facilitating a coordinated approach to public health responses and local and national preparation for emerging risks. Achieving this required mobilising diverse disciplinary and community stakeholders towards a unified and collaborative response to preventing drug related harms.
Keywords: co-design, co-creation, emerging drugs, Drug risk communication, Early warning system, new psychoactive substances (NPS), Counterfeit pharmaceuticals
Received: 03 Nov 2024; Accepted: 23 May 2025.
Copyright: © 2025 Siefried, Hill, Clifford, Brown, Camilleri, Crawford, Dessauer, Dilkes-Frayne, Freestone, Gobeil, Harrod, Hudson, Hull, Lenton, Lyons, Oh, Peacock, Pierce, Sidaway, Soderstrom, Tzanetis and Ezard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Krista J Siefried, the National Centre for Clinical Research on Emerging Drugs, Sydney, Australia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.